SINO_KW41.jpg

Sino Biological, a biotechnology company which provides biological research reagents and related technical contract research services, will be featured on Worldwide Business with kathy ireland, airing on FOX Business Network, Bloomberg International and other outlets as sponsored content. Hosted by business mogul Kathy Ireland, this award-winning television series takes an in-depth look at companies around the world currently impacting different sectors of business and society. Dr. Rob Burgess, Chief Business Officer for Sino Biological, will be interviewed.

Picture: Zukunft Industrie

The Who’s Who of the biotech industry relies on Austria. Every second biotechnology company is located in the hotspot of Vienna, where a leading research centre the Campus Vienna BioCenter has emerged. Multinationals and startups benefit from an extensive value chain, from basic research to production and distribution. The national investment promotion agency Austrian Business Agency (ABA) is the first point of contact when making the leap into the Austrian market.

Picture: istockphoto.com/ AlexRaths

What started in 2013 as an attempt – to offer experts in analytical and microbiological quality control, contract laboratories, representatives from authorities and service providers an
industry event and a platform for exchanging knowledge and  experience – has now become a firmly established date in the events calendar.

Idorsia CEO Jean-Paul Clozel © Idorsia

Bad news for Swiss drug discovery company Idorsia: Its Fabry disease hopeful lucerastat failed to reduce neuropathic pain in patients.

Since October, Dr. Gisèle Deblandre has strengthened the team of Cellbox Solutions GmbH in Norderstedt near Hamburg as Chief Scientific Officer.

Plenary session at Austria Business Center, #EFIB2021

Leading industry leaders, SMEs representatives and academia are joining in Vienna, Austria, at the 14th European Forum for Industrial Biotechnology and the Bioeconomy (EFIB), from 6th to 7th of October, organised by EuropaBio and conference partners.

Pharma giant AstraZeneca has submitted data to the US Food and Drug Administration (FDA) for  Emergency Use Authorization (EUA) of its antibody duo AZD7442.

Picture: EuropaBio

Medicines for rare and paediatric diseases have been successfully enabled through the EU’s incentives framework. The number of medicines in development has risen significantly since the introduction of the legislation (3,678 applications for orphan designation by end 2020).

CAR-T cell therapeutics are currently produced manually in the GMP laboratory at the Universitätsklinikum Heidelberg. This is extremely labour-intensive and has to be done in cleanroom environments at the highest Class A or B levels. Picture: Universitätsklinikum Heidelberg

Cell and Gene Therapy Processing?Personalised tumour treatments are expensive. This particularly applies to individual cancer therapies based on gene-modified T cells. Currently, they are produced manually or, at best, in a partially-automated process. In a collaboration project ProCell for Patient, two hospitals are currently working with Optima Pharma to develop an automated unit for the decentralised production of a CAR-T cell product in treatment centres.

Picture: Richter Helm

Richter-Helm is a leading and expanding Germany-based contract development and manufacturing organization (CDMO). Richter-Helm provides excellent services in the continuously growing market of pharmaceutical biotechnology. Offering a broad range of microbial manufacturing, development and analytical services, Richter-Helm will bring customer projects to the next level.